open access
Coronary slow flow is not an adverse prognostic factor in MINOCA patients in the 5-year follow-up
Affiliations- Department of Cardiology, Provincial Integrated Hospital, Plock, Poland
- Department of Cardiology and Internal Medicine, University of Warmia and Mazury, Olsztyn, Poland
- Department of Invasive Cardiology, Centre of Postgraduate Medical Education, Warsaw, Poland
- Department of Internal Medicine, Independent Public Complex of Healthcare Institutions, Zuromin, Poland
- Department of Cardiology, State Medical Institute of the Ministry of Interior, Warsaw, Poland
open access
Abstract
Introduction: The research aimed to compare the characteristics and outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA) patients with coronary slow flow (CSF) vs. normal coronary flow (no CSF) in a 5-year follow-up.
Material and methods: Between 2010–2015 were identified 111 patients as having final MINOCA diagnosis and available calculated corrected TIMI frame count (cTFC). CSF was defined as cTFC greater than 27 frames per second in any of the three coronary arteries. The primary endpoint was the 5-year major adverse cardiovascular events rate, defined as cardiac death, myocardial infarction, or hospitalization due to angina.
Results: The mean cTFC was 28.9 ± 6.1 frames per second (median: 28, IQR 24–33; min-max: 19–58). 62 (55.9%) patients had normal coronary flow, and 49 (44.1%) had CSF. Patients did not differ in sex (females no CSF vs. CSF: 58% vs. 61%, p = 0.7) or age (63 ± 15 years vs. 63 ± 13 years, p = 0.8). Patients with CSF characterized higher rates of chronic kidney disease (0 vs. 8.2%, p = 0.035). No statistically significant difference was observed for any of the analysed points. MACE rates for no CSF vs. CSF were 9.6% vs. 14.3% (HR 0.80, 95% CI 0.28–2.96, p = 0.7), respectively.
Conclusions: CSF was not associated with a higher risk of adverse events among MINOCA patients at five years.
Abstract
Introduction: The research aimed to compare the characteristics and outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA) patients with coronary slow flow (CSF) vs. normal coronary flow (no CSF) in a 5-year follow-up.
Material and methods: Between 2010–2015 were identified 111 patients as having final MINOCA diagnosis and available calculated corrected TIMI frame count (cTFC). CSF was defined as cTFC greater than 27 frames per second in any of the three coronary arteries. The primary endpoint was the 5-year major adverse cardiovascular events rate, defined as cardiac death, myocardial infarction, or hospitalization due to angina.
Results: The mean cTFC was 28.9 ± 6.1 frames per second (median: 28, IQR 24–33; min-max: 19–58). 62 (55.9%) patients had normal coronary flow, and 49 (44.1%) had CSF. Patients did not differ in sex (females no CSF vs. CSF: 58% vs. 61%, p = 0.7) or age (63 ± 15 years vs. 63 ± 13 years, p = 0.8). Patients with CSF characterized higher rates of chronic kidney disease (0 vs. 8.2%, p = 0.035). No statistically significant difference was observed for any of the analysed points. MACE rates for no CSF vs. CSF were 9.6% vs. 14.3% (HR 0.80, 95% CI 0.28–2.96, p = 0.7), respectively.
Conclusions: CSF was not associated with a higher risk of adverse events among MINOCA patients at five years.
Keywords
ischaemia with non-obstructive coronary arteries, INOCA, microcirculation dysfunction, acetylcholine, coronary flow reserve
About this articleTitle
Coronary slow flow is not an adverse prognostic factor in MINOCA patients in the 5-year follow-up
Journal
Issue
Article type
Original article
Pages
135-140
Published online
2023-06-06
Page views
1278
Article views/downloads
306
DOI
Bibliographic record
Medical Research Journal 2023;8(2):135-140.
Keywords
ischaemia with non-obstructive coronary arteries
INOCA
microcirculation dysfunction
acetylcholine
coronary flow reserve
Authors
Patryk Buller
Adam Kern
Maciej Tyczyński
Wojciech Rosiak
Wojciech Figatowski
Robert J. Gil
Jacek Bil
References (31)- Bil J, Pietraszek N, Pawlowski T, et al. Advances in Mechanisms and Treatment Options of MINOCA Caused by Vasospasm or Microcirculation Dysfunction. Curr Pharm Des. 2018; 24(4): 517–531.
- Bil J, Kern A, Bujak K, et al. Clinical characteristics and 12-month outcomes in MINOCA patients before and during the COVID-19 pandemic. Pol Arch Intern Med. 2023 [Epub ahead of print].
- Bil J, MoŻeŃska O, Segiet-ŚwiĘcicka A, et al. Revisiting the use of the provocative acetylcholine test in patients with chest pain and nonobstructive coronary arteries: A five-year follow-up of the AChPOL registry, with special focus on patients with MINOCA. Transl Res. 2021; 231: 64–75.
- Dreyer RP, Tavella R, Curtis JP, et al. Myocardial infarction with non-obstructive coronary arteries as compared with myocardial infarction and obstructive coronary disease: outcomes in a Medicare population. Eur Heart J. 2020; 41(7): 870–878.
- Chalikias G, Tziakas D. Slow Coronary Flow: Pathophysiology, Clinical Implications, and Therapeutic Management. Angiology. 2021; 72(9): 808–818.
- Gibson C, Cannon C, Daley W, et al. TIMI Frame Count. Circulation. 1996; 93(5): 879–888.
- Montone RA, Galiuto L, Meucci MC, et al. Coronary slow flow is associated with a worse clinical outcome in patients with Takotsubo syndrome. Heart. 2020; 106(12): 923–930.
- Saya S, Hennebry TA, Lozano P, et al. Coronary slow flow phenomenon and risk for sudden cardiac death due to ventricular arrhythmias: a case report and review of literature. Clin Cardiol. 2008; 31(8): 352–355.
- Poyraz E, Savaş G, Erdem A, et al. The Mean Corrected TIMI Frame Count Could Predict Major Adverse Cardiovascular Events in Patients with Coronary Slow-Flow Phenomenon. Turk Kardiyol Dern Ars. 2022; 50(4): 250–255.
- Zhu X, Shen H, Gao F, et al. Clinical Profile and Outcome in Patients with Coronary Slow Flow Phenomenon. Cardiol Res Pract. 2019; 2019: 9168153.
- Bil J, Pietraszek N, Gil RJ, et al. Complete Blood Count-Derived Indices as Prognostic Factors of 5-Year Outcomes in Patients With Confirmed Coronary Microvascular Spasm. Front Cardiovasc Med. 2022; 9: 933374.
- Magnani I, Toniolo S, Rinaldi A, et al. Coronary blood flow in myocardial infarction with nonobstructive coronary arteries. European Heart Journal. 2020; 41(Supplement_2).
- Vorobeva DA, Ryabov VV, Lugacheva JG, et al. Relationships between indicators of prothrombotic activity and coronary microvascular dysfunction in patients with myocardial infarction with obstructive and non-obstructive coronary artery disease. BMC Cardiovasc Disord. 2022; 22(1): 530.
- Mareai RM, Mohammed AQ, Zhang H, et al. Prognostic implication of coronary slow flow assessed by cTFC in patients with myocardial infarction with Non-obstructive coronary arteries. Eur J Intern Med. 2023; 108: 74–80.
- Hu F, Lu F, Huang X, et al. Relationship Between Plasma Total Homocysteine Levels and Mean Corrected TIMI Frame Count in Patients with Acute Myocardial Infarction. Int J Gen Med. 2021; 14: 8161–8172.
- Bossard M, Gao P, Boden W, et al. Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. Heart. 2021; 107(21): 1739–1747.
- Schmitz K, Groth N, Mullvain R, et al. Prevalence, Clinical Factors, and Outcomes Associated With Myocardial Infarction With Nonobstructive Coronary Artery. Crit Pathw Cardiol. 2021; 20(2): 108–113.
- Gasior P, Desperak A, Gierlotka M, et al. Clinical Characteristics, Treatments, and Outcomes of Patients with Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA): Results from a Multicenter National Registry. J Clin Med. 2020; 9(9).
- Lindahl B, Baron T, Erlinge D, et al. Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease. Circulation. 2017; 135(16): 1481–1489.
- Kunadian V, Chieffo A, Camici PG, et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. EuroIntervention. 2021; 16(13): 1049–1069.
- Heggie R, Briggs A, Stanley B, et al. Stratified medicine using invasive coronary function testing in angina: A cost-effectiveness analysis of the British Heart Foundation CorMicA trial. Int J Cardiol. 2021; 337: 44–51.
- Goel PK, Gupta SK, Agarwal A, et al. Slow coronary flow: a distinct angiographic subgroup in syndrome X. Angiology. 2001; 52(8): 507–514.
- Arbel Y, Rind E, Banai S, et al. Prevalence and predictors of slow flow in angiographically normal coronary arteries. Clin Hemorheol Microcirc. 2012; 52(1): 5–14.
- Diver DJ, Bier JD, Ferreira PE, et al. Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial). Am J Cardiol. 1994; 74(6): 531–537.
- Cannon RO. Microvascular angina and the continuing dilemma of chest pain with normal coronary angiograms. J Am Coll Cardiol. 2009; 54(10): 877–885.
- Mangieri E, Macchiarelli G, Ciavolella M, et al. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn. 1996; 37(4): 375–381, doi: 10.1002/(SICI)1097-0304(199604)37:4<375::AID-CCD7>3.0.CO;2-8.
- Bil J, Tyczyński M, Modzelewski P, et al. Acetylcholine provocation test with resting full-cycle ratio, coronary flow reserve, and index of microcirculatory resistance give definite answers and improve health-related quality of life. Kardiol Pol. 2020; 78(12): 1291–1292.
- Li M, He Y, Cheang I, et al. Clinical characteristics and outcome in patients with ST-segment and non-ST-segment elevation myocardial infarction without obstructive coronary artery: an observation study from Chinese population. BMC Cardiovasc Disord. 2022; 22(1): 21.
- Wang Y, Zhao HW, Wang CF, et al. Incidence, Predictors, and Prognosis of Coronary Slow-Flow and No-Reflow Phenomenon in Patients with Chronic Total Occlusion Who Underwent Percutaneous Coronary Intervention. Ther Clin Risk Manag. 2020; 16: 95–101.
- Sadr-Ameli MA, Saedi S, Saedi T, et al. Coronary slow flow: Benign or ominous? Anatol J Cardiol. 2015; 15(7): 531–535.
- Huyut MA. Comparison of the Outcomes between Coronary No-Reflow and Slow-Flow Phenomenon in Non-STEMI Patients. Arq Bras Cardiol. 2021; 116(5): 856–864.